Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: London’s Metropolitan Police said the company had been charged with seven counts of supplying a medicinal product which was not of the nature or quality specified in the prescription. It was also accused of failing to take all reasonably practicable steps to ensure that patients were not infected by contaminants. The north London company said in a statement: “As founders of ITH we have every sympathy for all the families affected, regardless of the cause. However, we are disappointed by the decision to charge the company and will vigorously defend this case.”  The police investigation was launched in September 2014 following the death of a baby three months earlier at London’s Guy’s and St Thomas’ hospital. The death of a second baby at the same hospital and a third at the Rosie Maternity Hospital in Cambridge, central England, in June 2014 were then also investigated. The inquiry followed an outbreak of a bacterial infection that affected some babies receiving Total Parental Nutrition (TPN), an intravenous feed. The seven babies involved in the investigation, including the three who died, had all received the feed. The investigation established that the cause of death of the first baby could be linked to TPN, although the deaths of the other two were not found to be linked. Five hospitals in total were involved in the investigation, the other three being Russells Hall Hospital in Dudley, Luton and Dunstable Hospital and Lister Hospital in Stevenage, all in central England. ITH Pharma, which was founded in 2008, said it had manufactured more than 1.4-million components of TPN since its launch and was the sole commercial supplier of reactive feeding solutions to the National Health Service. “This product has helped thousands of extremely vulnerable infants survive premature and complex births,” it said. The case is due to start at Westminster Magistrates’ Court in London on Dec. 17. Claim: UK police charge pharmaceutical company over hospital baby deaths.

A: Police said on Wednesday they had charged pharmaceutical company ITH Pharma with a number of offences as part of an investigation into the deaths and illnesses of seven babies at several hospitals.
****
Q: Paragraph: The Kansas Department of Health and Environment announced Wednesday it is partnering with Count the Kicks, a stillbirth prevention public health campaign. Kansas officials say the state records an average of 232 stillborn deaths each year. The campaign seeks to save 60 babies every year by decreasing Kansas’ stillbirth rate by 26 percent. The effort achieved that reduction in Iowa. Count the Kicks encourages expectant moms to track their baby’s movements once a day in the third trimester to determine how long it normally takes their child to get to 10 movements. If moms notice a change in the baby’s normal pattern, they are encouraged to call their doctors. Claim: Kansas launches campaign to reduce stillbirth rate in state.

A: The state is promoting a campaign to reduce the number of stillborn deaths in Kansas.
****
Q: Paragraph: The story does not describe the costs of uterine artery embolization or how they compare to costs of surgery. The cost of UAE is quite high and for some women may not be covered by insurance. The story provides adequate quantification of some of the most important things for consumers to know, such as the fact that after a year, there were no differences in the quality of life of the women assigned to uterine artery embolization compared to those assigned to surgery and that 13% of those who underwent UAE had a repeat hospitalization, mostly for surgical intervention because of failure of UAE to achieve the desired results. The story could have provided more quantification of other pieces of information that women would want to know, such as length of hospital stay, time to return to work, or risk of serious adverse events. The story does mention some of the potential harms of uterine artery embolization, such as the need for repeat procedures for treatment of recurrent symptoms and the fact that there are questions about safety of pregnancy after the procedure. The story should have also mentioned the potential for ovarian failure, causing infertility, infection, delayed complications and a small risk of emergency hysterectomy. The story adequately describes the design of the current study. The story accurately describes the prevalence and symptoms of uterine fibroids. The story only uses quotes from the original article and accompanying editorial. It doesn't appear that the authors were even interviewed. The story should have quoted other clinicians/researchers who were not related to the study who could have provided some perspective on what this new information means for clinical practice. The story does mention alternative options such as myomectomy (surgical removal of the fibroids), hysterectomy (surgical removal of the uterus) in addition to uterine artery embolization. The story could have mentioned other treatments such as watchful waiting, pain medications or birth control pills. The story does not state whether uterine artery embolization (UAE) is available and if so, how widely. And availability is a real issue. It requires expertise in interventional vascular radiology and an interest in the female pelvic anatomy. Facilities offering the procedure would need strong links between gynecologists and radiologists to provide coordinated assessment and care. This is not explained in the piece. The story implies that uterine artery embolization is a new procedure. The story could have mentioned that the procedure has been performed for more than 10 years in Europe and the US, although it has been limited to mostly academic hospitals. There is no way to know if the story relied on a press release as the sole source of information, although it is noteworthy that the story only uses quotes lifted from the published study and from an accompanying editorial. It doesn't appear that these people were actually interviewed. Claim: Treating fibroids without surgery

A:
A growing body of evidence suggests that uterine artery embolization (UAE) is a viable alternative to surgery for symptomatic fibroids for women who don't desire future pregnancy. For many women, avoiding surgery is a tremendous relief. However, there are still unanswered questions about the safety and efficacy of UAE. This story reports on a randomized controlled trial published in this week's New England Journal of Medicine comparing UAE to surgery for symptomatic fibroids. This story does a good job of explaining the problem of fibroids, describing the treaments compared and why UAE is an important advancement. However, this story is limited by the lack of balance in its sources and leaving out important information on the costs and availability of the procedure. The story accurately describes the prevalence and symptoms of uterine fibroids. The story provides adequate quantification of some of the most important things for consumers to know, such as the fact that after a year, there were no differences in the quality of life of the women assigned to UAE compared to those assigned to surgery and that 13% of those who underwent UAE had a repeat hospitalization, mostly for surgical intervention because of failure of UAE to achieve the desired results. The story could have provided more quantification of other pieces of information that women would want to know, such as length of hospital stay, time to return to work, or risk of serious adverse events. The story implies that UAE is a new procedure. The story could have mentioned that the procedure has been performed for more than 10 years in Europe and the US. The story does mention some of the potential harms of UAE, such as the need for repeat procedures for treatment of recurrent symptoms and the fact that there are questions about safety of pregnancy after the procedure. The story should have also mentioned the potential for ovarian failure, causing infertility, infection, delayed complications and a small risk of emergency hysterectomy. However, the story does not state whether uterine artery embolization (UAE) is available and if so, how widely. And availability is a real issue. It requires expertise in interventional vascular radiology and an interest in the female pelvic anatomy. Facilities offering the procedure would need strong links between gynecologists and radiologists to provide coordinated assessment and care. This is not explained in the piece. The story also does not describe the costs of UAE and how they compare to costs of surgery. The cost of UAE is quite high and for some women may not be covered by insurance.
****